IvanaGojoMD

Associate Professor of Oncology, Johns Hopkins University School of Medicine; Associate Professor of Oncology, Co-Director, Leukemia Drug Development Program

Join to view full profile

Dr. Gojo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gojo's full profile

Already have an account?

Office
600 N Wolfe St
Baltimore, MD 21287
Phone+1 410-955-9441

Fax+1 410-328-6896

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1998 - 2001
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 1995 - 1998
University of Zagreb Faculty of MedicineClass of 1992

Certifications & Licensure

MD State Medical License 2001 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes Start of enrollment: 2005 Dec 01
Completed
Phase 1
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Start of enrollment: 2010 Apr 01
Completed
Phase 1
Veliparib and Temozolomide in Treating Patients With Acute Leukemia Start of enrollment: 2010 May 21
Active, not recruiting
Phase 1
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2013 Dec 16
Completed
Phase 1
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Start of enrollment: 2017 Oct 25
Active, not recruiting
Phase 1
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML Start of enrollment: 2016 Aug 11
Completed
Phase 1
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 1, Phase 2
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Start of enrollment: 2023 Jul 06
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

6 citations
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Rory M Shallis, Naval Daver, Jessica K Altman, Rami S Komrokji, Daniel A Pollyea
The Lancet. Haematology. 2023-09-01
152 citations
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Christopher G. Kanakry, Hua Ling Tsai, Javier Bolaños-Meade, B. Douglas Smith, Ivana Gojo
Blood. 2014-12-11
14 citations
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibr...
Tania Jain, Hua-Ling Tsai, Amy E DeZern, Lukasz P Gondek, Hany Elmariah
Transplantation and Cellular Therapy. 2022-05-01

Journal Articles

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...
Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research

Abstracts/Posters

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall...
Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...
Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
Ivana Gojo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Authored Content

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018